Carboplatin Therapeutic Drug Monitoring in Intermittent Hemodialysis-A Case Report and Review of the Literature.

IF 3.2 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-03-20 DOI:10.1016/j.clinthera.2025.02.007

Martin Christian Bucher, Daniel Andreas Bossard, Marco Bonani, Michael Paul, Christopher Geinitz, Jérôme Bonzon

引用次数: 0

Abstract

Purpose: We present the case of a 45-year-old female patient with hemodialysis-dependent renal failure due to FSGS who was diagnosed with FIGO IIIc ovarian cancer and treated with carboplatin/gemcitabine under hemodialysis.

Methods: A carboplatin dose of 200 mg/m² was administered (target AUC 4.0 min*mg/mL). Hemodialysis was started 2 hours after carboplatin administration and continued over 4 hours, with an additional dialysis session the day after.

Findings: The measured AUC was 5.8 min*mg/mL.

Implications: A dose reduction to 250 mg resulted in an AUC of 2.3 min*mg/mL. This is the first case of an ovarian cancer treated with a high-dose scheme of carboplatin under hemodialysis.

查看原文本刊更多论文

间歇性血液透析中的卡铂治疗药物监测--病例报告和文献综述。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.